v3.26.1
Disaggregated Revenues
 6 Months Ended
Jun. 30, 2026
Disaggregation of Revenue [Abstract]  
Disaggregated Revenues Disaggregated Revenues
The following table provides information regarding total revenues (dollars in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
(unaudited)(unaudited)
Net product sales
Qelbree$89,239 $77,547 $167,082 $142,292 
GOCOVRI37,530 36,660 72,770 67,349 
ONAPGO13,546 1,604 21,921 1,604 
Trokendi XR8,411 11,193 17,890 23,994 
Oxtellar XR8,782 11,637 16,204 21,835 
APOKYN6,323 12,820 14,051 27,796 
Other(a)
1,882 6,534 6,548 15,113 
Total net product sales165,713 157,995 316,466 299,983 
Collaboration revenue (ZURZUVAE)(b)
35,350 — 62,993 — 
Royalty, licensing, and other revenues17,995 7,458 47,304 15,294 
Total revenues$219,058 $165,453 $426,763 $315,277 
___________________________________________
(a) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
(b) Includes the Company's proportionate share of net sales of ZURZUVAE.
The Company recognized $20.0 million of licensing revenue in the six months ended June 30, 2026 related to the achievement of a commercial milestone under the Company's collaboration agreement with Shionogi.
Adjustments related to prior year sales for the six months ended June 30, 2026 were approximately 1% of net product sales. Adjustments related to prior year sales for the six months ended June 30, 2025 were approximately 4% of net product sales. In 2025, the Company had favorable actual returns experience and as a result, the Company changed its estimated provision for product returns based on the most recent experience. Adjustments related to prior year sales for the six months ended June 30, 2025 were primarily attributable to Qelbree.
We do not currently own or operate manufacturing facilities for the commercial production of any of our commercial products. We currently depend on third-party clinical manufacturing organizations (CMOs), who offer a comprehensive range of contract manufacturing and packaging services, in various countries for the supply of active product ingredients (API), and finished goods for our commercial products. For most of our commercial products, we rely on single source suppliers to produce and package final dosage forms for our products and raw materials, including API.

On November 4, 2025, the Company announced that due to stronger than expected demand for ONAPGO, supplier constraints were impacting the Company's ability to fully meet this demand. ONAPGO is manufactured in Europe, supplied to us by our ONAPGO licensing partner, and packaged in the U.S. by a third-party CMO. The Company relies on single source suppliers to produce and package final dosage forms for ONAPGO. In February 2026, the Company announced that it has made progress in securing additional product supply of ONAPGO from the current supplier and, as a result, has resumed new patient initiation. In addition, the Company is working with a second supplier that is expected to begin supplying ONAPGO in 2027, provided regulatory approval is obtained. Any changes in any of the suppliers would require regulatory approval which could cause a further delay in manufacturing and a possible loss of sales, which could affect future operating results adversely.